Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management

Yu-Wen Zhou¹, Qian Xu², Yan Wang³, Ruo-Lan Xia¹, Ji-Yan Liu¹, Xue-Lei Ma¹

¹Department of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
²West China Medical Publishers, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China
³Department of Oncology, West China Hospital of the First People’s Hospital of Long Quan Yi District, Chengdu 610041, Sichuan Province, China

Co-first authors: Yu-Wen Zhou, Qian Xu, and Yan Wang

Correspondence to: Ji-Yan Liu and Xue-Lei Ma. Department of Biotherapy and Cancer Center, West China Hospital, Sichuan University, 37 Guoxue Xiang Street, Chengdu 610041, Sichuan Province, China. liujiyan1972@163.com; drmaxuelei@gmail.com

Received: 2021-07-15        Accepted: 2021-11-02

Abstract

● Immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 receptor/ligand have revolutionized cancer treatment, achieving unprecedented efficacy in numerous malignancies. Despite the excellent therapeutic effects of ICIs, medications, such as pembrolizumab, ipilimumab, nivolumab, atezolizumab, avelumab, and durvalumab, typically cause a broad spectrum of toxicity events termed as immune-related adverse events (irAEs). Among these irAEs, ophthalmic adverse events occur infrequently and are not comprehensively recognized. The current understanding of ophthalmic irAEs is primarily derived from case reports and case series (Table 1)


INTRODUCTION

Immune checkpoint inhibitors (ICIs) that target cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 receptor/ligand (PD-1/PD-L1) pathways have shown robust evidence of antitumor activity in patients with cancer. These medications include pembrolizumab, ipilimumab, nivolumab, atezolizumab, avelumab, and durvalumab, which have been approved by the Food and Drug Administration (FDA) for numerous cancer therapies. With the progressive implementation of ICIs in clinical practice, however, a key challenge has emerged: the uncontrolled collateral effects of ICIs on the immune system, which can result in immune-related adverse events (irAEs) that can affect all organ systems. irAEs comprise common adverse events, such as dermatological, gastrointestinal, hematological, pulmonary, and rheumatic toxicities, nephritis, and endocrinopathy. They also include rare adverse events (arising in <1% of patients), such as neurological, ocular, and cardiac toxicities, which can largely be controlled by glucocorticoid therapy. Among these toxicities, ophthalmic irAEs, including dry eye, uveitis, ocular myasthenia gravis, uveal effusion, retinal detachment, and conjunctivitis occur infrequently and are not comprehensively recognized. The current understanding of ophthalmic irAEs is primarily derived from case reports and case series. In this review, based on relevant articles in the literature and current evidence, we summarize the incidences, manifestations, diagnoses, underlying mechanisms, treatments, and outcomes of ophthalmic irAEs and discuss possible management strategies. A better understanding of these features is critical for managing patients with ICI-associated ophthalmic adverse events.

● KEYWORDS: immune checkpoint inhibitor; ophthalmological adverse events; uveitis; neuro-ophthalmic toxicity; retinopathy

DOI: 10.18240/ijo.2022.04.19

POTENTIAL MECHANISM OF OPHTHALMIC TOXICITY

The mechanism of ICI-associated ophthalmic events has yet to be fully understood. The eyes have special mechanisms...
cases, and orbital myopathy in 1 case. Intraocular inflammation was reported in 5 cases, ocular surface disease in 2 degrees; as a consequence, these tumor cells can potentially interact with PD-1 and CTLA-4, respectively. The epithelial cells express both PD-L1 and CD86, which can downregulate the inflammatory T-cell activity, retinal pigment leading to ocular adverse events due to ICI therapy. To further reactions, Blockade of these regulatory T cells may trigger adverse events is <1%. The study recently attempted to explore the relationship between ICIs and ocular adverse events in 745 patients and observed intraocular inflammation in 5 cases, ocular surface disease in 2 cases, and orbital myopathy in 1 case. One study has shown that patients receiving ICIs as therapy who developed colitis were also susceptible to episcleritis or uveitis. Ocular irAEs can occur at any time during treatment, and even after the cessation of ICIs. However, most (approximately 70%) irAEs typically occur within two months after the initiation of therapy. A minority of irAEs occurs after 48 wk, and these irAEs can involve various parts of the eye and orbit. We reviewed published cases of adverse ophthalmic reactions and found that the time to onset of ophthalmic irAEs was earlier when combined with ICIs (either with other ICIs or other conventional therapies; Figure 2). Apart from the variability of the time to onset, there is variability in the ocular symptoms: the most common clinical manifestation of ICI-related ophthalmic toxicity is dry eyes (3%-24%), uveitis (1%), and myasthenia gravis involved with the eyes (frequency undefined). Other less common ophthalmic adverse events include uveal effusion, retinal detachment, conjunctivitis, ocular myositis, vasculitis, keratitis, episcleritis, vitritis, choroidopathy, and a broad spectrum of neuro-ophthalmic toxicities (Figure 1). Information on various types of ocular adverse events are summarized in Table 2. Most of these adverse reactions can be effectively controlled by periocular, topical, or systemic corticosteroids. DRY EYE DISEASE Dry eye disease is a presentation that is characterized by tear hyperosmolarity, tear-film instability, ocular surface inflammation, and damage due to reduced tear quantity and/or quality. Dry eye disease associated with ICIs was the first and the most frequently reported ocular surface adverse event with an incidence ranging from 3% to 24% and presenting with nonspecific eye irritation and as a part of the sicca syndrome. It can also lead to corneal perforation. ICI-related dry eyes can be effectively managed with topical cyclosporine and artificial tears. One patient had nivolumab-associated corneal graft rejection and did not respond well to systemic or subconjunctival corticosteroids. UVEITIS Uveitis refers to the inflammation of the uvea, a highly vascularized layer between the retina and sclera. Among all ophthalmic toxicities, uveitis is one of the most common adverse reactions. It is associated with anti-CTLA-4 and anti-PD-1/PD-L1 agents, such as ipilimumab, durvalumab, avelumab, pembrolizumab, nivolumab, and atezolizumab.

<table>
<thead>
<tr>
<th>Case reports/series</th>
<th>Patients</th>
<th>Cancer type</th>
<th>Drugs</th>
<th>Time of onset</th>
<th>Symptoms</th>
<th>Ophthalmologic events</th>
<th>Withdraw the drug</th>
<th>Treatment</th>
<th>The time of recovery</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aris et al 2017[15]</td>
<td>55y/M</td>
<td>Melanoma</td>
<td>Nivolumab</td>
<td>2wk after the first infusion</td>
<td>Blurry vision</td>
<td>Acute anterior uveitis with VKH-like eruptions</td>
<td>Yes</td>
<td>Steroid</td>
<td>NR</td>
<td>Improved</td>
</tr>
<tr>
<td>Baughman et al 2017[16]</td>
<td>92y/F</td>
<td>Melanoma</td>
<td>Nivolumab</td>
<td>After the third infusion</td>
<td>Bilateral blurred vision</td>
<td>Bilateral uveitis and keratitis</td>
<td>No</td>
<td>Systemic and topical steroid</td>
<td>Within 2wk</td>
<td>Improved</td>
</tr>
<tr>
<td>Carrera et al 2017[17]</td>
<td>68y/M</td>
<td>NSCLC</td>
<td>Tremelimumab and durvalumab</td>
<td>4d after the second infusion</td>
<td>Binocular vertical diplopia, ptosis of left upper eyelid</td>
<td>Inflammatory myopathy affecting the extraocular muscles</td>
<td>No</td>
<td>Systemic steroids</td>
<td>1mo</td>
<td>Improved</td>
</tr>
<tr>
<td>Conrady et al 2018[18]</td>
<td>57y/M</td>
<td>Melanoma</td>
<td>Pembrolizumab</td>
<td>After 15 infusion</td>
<td>Bilateral, acute vision loss</td>
<td>Uveitis</td>
<td>Yes</td>
<td>Oral steroids</td>
<td>2wk</td>
<td>Improved</td>
</tr>
</tbody>
</table>

ICI-associated ophthalmic adverse events

Figure 1 Anatomical diagram of the eye Immune checkpoint inhibitors associated ophthalmic adverse events are indicated based on the affected ocular structure.

Figure 2 Time to onset of immune checkpoint inhibitors-associated ophthalmic adverse events This figure is built based on the therapy types (monotherapy and combined therapy) of cases. The time when the ICIs-related ophthalmic toxicity occurred is recorded as a dot: the blue dot represents monotherapy and the red dot represents combined therapy. Two pie charts illustrate case percentages of different onset time periods in each group.

Table 2 Information on various types of ocular adverse events

<table>
<thead>
<tr>
<th>Type of ocular irAEs</th>
<th>Study design</th>
<th>Sample size</th>
<th>Drug employed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uveitis</td>
<td>Case reports/series</td>
<td>15</td>
<td>Nivolumab/ipilimumab/pembrolizumab/atezolizumab/ipilimumab+nivolumab</td>
</tr>
<tr>
<td>Dry eye</td>
<td>Case reports</td>
<td>4</td>
<td>Nivolumab/pembrolizumab</td>
</tr>
<tr>
<td>Optic nerve</td>
<td>Case reports</td>
<td>5</td>
<td>Atezolizumab/nivolumab/ipilimumab</td>
</tr>
<tr>
<td>VKH-like syndrome</td>
<td>Case reports</td>
<td>8</td>
<td>Nivolumab/ipilimumab</td>
</tr>
<tr>
<td>Uveal effusion</td>
<td>Case reports</td>
<td>3</td>
<td>Atezolizumab/nivolumab</td>
</tr>
<tr>
<td>Retinal detachment</td>
<td>Case reports</td>
<td>6</td>
<td>Pembrolizumab/atezolizumab/ipilimumab/nivolumab</td>
</tr>
<tr>
<td>Orbital inflammation</td>
<td>Case reports/series</td>
<td>10</td>
<td>Ipilimumab/pembrolizumab/nivolumab/tremelimumab</td>
</tr>
<tr>
<td>Inflammatory myopathy</td>
<td>Case reports</td>
<td>4</td>
<td>Tremelimumab+durvalumab/pembrolizumab/ipilimumab</td>
</tr>
<tr>
<td>Thyroid eye disease</td>
<td>Case reports</td>
<td>4</td>
<td>Ipilimumab/nivolumab/tremelimumab</td>
</tr>
</tbody>
</table>

There is a lack of data for comparing the incidence, pattern, and occurrence time of uveitis induced by CTLA-4 with PD-1/PD-L1 inhibitors[38]. Uveitis irAEs can occur in approximately 1% of patients and manifest as anterior-[39-47], posterior-[48], or pan-uveitis[49]. The time to onset after the initial infusion of ICIs ranges broadly from approximately 2wk to 14mo (median time is 9wk). A typical initial chief complaint is conjunctival redness or bilateral blurred vision[50]. Other symptoms, such as eye pain, photophobia, and floaters are also observed with uveitis[45]. Nevertheless, the mechanisms of uveitis irAEs have yet to be assessed comprehensively[23].

Patients with uveitis irAEs can use periocular, topical, or systemic corticosteroids to control inflammation, and intravitreal corticosteroids can be used for treating macular edema[46,51]. Some severe cases particularly require the cessation of ICI therapy.

Vogt-Koyanagi-Harada (VKH) disease, known as a bilateral diffuse granulomatous uveitis, is diagnosed in patients who receive anti-PD-1 agents[13]. It presents with blurry vision, xanthopsia, and exudative retinal detachments with bilateral uveitis and is amenable to systemic and occasional topical corticosteroid therapy[13,52-53].

**Orbit and Ocular Adnexa** Myasthenia gravis involved with the eye is the most frequently reported adverse event of orbital and ocular adnexa[54-60]. It can present with blepharoptosis, ocular motility abnormalities, diplopia, or severe systemic symptoms in addition to respiratory distress[55-60]. These symptoms can be managed with oral/intravenous corticosteroids, intravenous immunoglobulin, pyridostigmine, and plasmapheresis. Severe consequences, such as death from respiratory failure, have also been recorded[61].

ICI-associated inflammatory orbitopathy is an orbital adverse effect that presents with proptosis, pain, eyelid edema, chemosis, and extraocular motility restriction. One case of orbital myopathy that involved the extraocular muscles was associated with blepharoptosis and dyspnea and required temelimumab and durvalumab discontinuation and the use of systemic corticosteroids[15].

Thyroid-like orbitopathy, characterized by ophthalmoplegia due to extraocular muscle involvement and proptosis, may occur in patients treated with ipilimumab even in the absence of thyroid dysfunction[62-63]. It has been suggested that anti-CTLA-4 agents enhance the activation and proliferation of CD8+ T lymphocytes, facilitating the development of Grave’s orbitopathy[64]. Anti-CTLA-4 in combination with an anti-PD-L1 inhibitor has also shown to be related to Grave’s orbitopathy and an inflammatory myopathy of the diplopia, extraocular muscles, ptosis, and weakness[65-67]. Moreover, inflammatory orbitopathy, orbital inflammatory syndromes, and orbital apex syndrome have been described in several studies[68-69]. Systemic corticosteroids can be used to manage these patients[68,70].

**Optic Nerve** Neuro-ophthalmic adverse events were first reported in a pediatric patient with grade 4 glioblastoma multiforme in 2018[71]. It has also been shown to be associated with ipilimumab[72], but the incidence is very low. Several cases with neurologic adverse events, including optic neuritis, Grave’s orbitopathy, papillitis, and myasthenia gravis have been reported to occur at a median onset of 35d after ICI therapy[73-77]. Papilledema, multiple cranial neuropathies, and cerebellar ataxia with associated nystagmus have also been observed[78-79]. The manifestations of neuro-ophthalmic adverse events range from mild to severe and present with visual disturbances, including part or full-field vision loss, disc edema, or scotomas[73,80]. Prompt recognition, treatment, and management are crucial to prevent morbidity[81]. Most symptoms can be alleviated with corticosteroids, but some severe optic neuropathy requires intravenous immunoglobulin or plasmapheresis[73]. Of note, severe ophthalmoplegia induced by immunotherapy requires early intervention and treatment because of potentially fatal side events[82-83].

**Retinal Detachment** Uveal effusion has been reported in patients treated with anti-PD-1/PD-L1 agents, such as pembrolizumab, nivolumab, and atezolizumab. ICI-associated uveal effusion usually manifests as symptoms, such as redness, blurry vision, ocular, and serous choroidal detachment including the foveal presence of intraretinal and subretinal fluid[19]. Although the uveal effusion can also be attributed to intraocular inflammation, ICI-related uveal effusion can resolve after discontinuing the immunotherapy, indicating that ICIs play an important role in causing uveal effusions[19].

There are isolated reports of serous retinal detachment with or without choriodopathy[84-85], immune retinopathy[80], exudative retinal detachment with ciliochoroidal effusion[86] and melanoma-associated retinopathy with atypical chorioretinal lesions[87] leading to photophobia and blurry vision that have been treated with variable therapies, including topical and oral corticosteroids, discontinuation of ICIs, or observation alone[86]. Early cessation of checkpoint inhibitors has favorable visual acuity outcomes[84].

**Conjunctivitis** Conjunctivitis in patients treated by ICIs is rarely reported, and the incidence and time to onset varies by patient. In one case study, the patient complained of irritated red eyes without the impairment of vision after 13 doses of nivolubam[29]. Conjunctiva swab test was negative, and symptoms were not relieved after antibiotic ocular drop treatment. The ophthalmologist’s examination revealed bilateral sterile conjunctivitis with no signs of retinal or uveitis lesions. The manifestation was partially improved after topical steroid therapy. Two cases of conjunctivitis have been
ICI-associated ophthalmic adverse events

reported in a retrospective study, presenting with irritation and conjunctival injection; however, neither required ICI discontinuation\[39,49\]. One case improved after treatment with topical corticosteroids\[39\].

**Other Diseases**

Ocular myositis was reported in a case with metastatic renal carcinoma. Symptoms such as a subacute presentation of bilateral eyelid ptosis and painless ophthalmoplegia were observed after the second infusion of pembrolizumab. A mild elevation of TSH and CK was found in laboratory tests. A physical examination indicated complete, non-fluctuating, external ophthalmoplegia with bilateral eyelid ptosis\[88\]. Deltoid muscle biopsy demonstrated mixed macrophagic/lymphocytic endomysial inflammatory infiltration, with prevalent CD68 and CD8 cells, sometimes expressing PD-1/PD-L1 antigens.94 MHC-I overexpression in the cytoplasm and sarcolemma was observed in non-necrotic cell clusters. In perifascicular regions, CD56+ cells were also observed. After starting corticosteroid therapy and discontinuing pembrolizumab, the patient’s symptoms were relieved and the laboratory tests normalized\[88\].

Retinal vasculitis resulting in blurry vision secondary to pembrolizumab has been reported in the setting of metastatic cutaneous melanoma to the vitreous cavity. One patient complained of blurred vision and was treated with prednisolone eye drops. Pembrolizumab was continued, and the tumor lesion achieved complete response after 15 cycles of treatment. The ocular presentation improved after external beam radiotherapy and vitrectomy for the vitreous metastases\[89\].

The granulomatous inflammation of lacrimal glands has been rarely reported\[99-101\]. The pathogenesis of granulomatous infiltration in the context of ICIs may be attributed to IL-2 secretion by activated T cells and lymphocytic infiltration with CD8+ T cells\[82\]. One patient with simultaneous and bilateral keratitis and uveitis in the setting of nivolumab therapy for metastatic melanoma was presented in a case report. The patient presented with bilateral blurred vision after the third dose of nivolumab. Other keratitis types mainly present with corneal haze and pain and can be managed with topical corticosteroids\[14\]. Episcleritis induced by ipilimumab was also reported in clinical trials; however, details on therapy and outcomes were not given\[99\].

**DIAGNOSING IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED OPHTHALMIC TOXICITY**

Patients with ophthalmic irAEs require thorough ophthalmologic tests that can assess the presence of ophthalmologic, fundus, neurologic, and systemic disease (Figure 3). Ophthalmic evaluation is the most common form of diagnosis; nearly all patients with ICI-associated ophthalmic toxicity were identified in this manner\[94-95\] (Figure 3). Patients with ICI-related ophthalmic toxicity accompanying with fever and flu-like symptoms were recommended treatment with antinuclear antibody during the periods of adverse events\[96\]. Of note, antinuclear antibody usually has good sensitivity but poor specificity for autoimmune disease. The antinuclear antibody evaluation, either using absolute values or changes from baseline, is required to better understand the diagnostic and predictive value in cases with ocular immune-associated adverse reactions\[96\].

The examination of neuro-ophthalmic events may be accompanied by a series of imaging studies and ancillary laboratories based on medical history and examination findings, including infectious and autoimmune serologies, MRI, optical coherence tomography (OCT), and cerebrospinal fluid (CSF) examination\[97\]. Orbital and cerebral MRI may provide ophthalmologist with valuable diagnostic and prognostic information\[98\].

A significant reduction in the visual acuity associated with a nonpainful redness in both eyes was found in ophthalmologic evaluation\[28\]. Slit-lamp examination revealed the presence of anterior chamber cells of strong positive, bilateral granulomatous keratic precipitates, bilateral anterior, and posterior synechiae and some pigmentary deposits on the anterior lens capsule that were predominant in the left eye. Fluorescein angiography confirmed unilateral or bilateral papilledema. A light macular edema associated with a subfoveal serous retinal detachment can be revealed via OCT\[28\].

A wide spectrum of ocular manifestations should be included in the differential diagnosis by ophthalmologists to prevent irreversible vision loss and mortality\[82-83\]. It is worth mentioning that melanoma-associated retinopathy, a rare autoimmune disease, has been shown to be associated with the diagnosis of cutaneous melanoma\[91\]. It is characterized by various optic disc findings and the presence of antiretinal antibodies. Melanoma-associated retinopathy presents with several forms of chronic visual impairments, which usually develop several months after the diagnosis of melanoma\[33,38\]. Melanoma-associated retinopathy occurs with the melanoma diagnosis, regardless of the therapy, and is therefore easily distinguished from ICI-associated ocular toxicity\[87\].

**TREATMENT AND OUTCOME OF ICI-ASSOCIATED OPHTHALMIC EVENTS**

The treatment regimens for ophthalmic irAEs vary depending on the case. Recently, detailed recommendations for the treatment of ICI-induced ophthalmic adverse events have been proposed. For patients with moderate adverse events (CTCAE grade 2, such as those involving the anterior segment), ICIs should be suspended until the symptoms reduce to grade 1 or normalize; corticosteroids may be administered. For patients with severe adverse events (grade 3 or 4, such as those involving the posterior segment), systemic corticosteroids
should be administered. Large doses and long periods of corticosteroids should be avoided because of multiple adverse events that result from it[100].

In addition to being considered as a drug-associated toxicity, some ophthalmic toxicities, such as uveitis, may serve as a prognostic marker of response to ICIs. Attia et al[101] reported a series of 56 metastatic melanoma patients treated with ipilimumab and found that autoimmunity correlated with the regression of tumor. Among those with severe irAEs, 36% had objective tumor regression compared with 5% of those without irAEs. There was also a report in which one patient developed severe ophthalmic adverse event during treatment with ipilimumab; however, the patient sustained tumor remission[37]. Of the 15 reviewed cases, tumor regression upon manifestation of uveitis was described in 7 cases in which either a complete or partial response was obtained[50]. There was a report of a case who was treated with pembrolizumab and soon developed symptoms, including blurred vision, hearing loss, and acute onset ataxia. Simultaneously, a robust regression of metastases was also detected[36]. Some severe adverse events of panuveitis, such as a VVKH syndrome induced by ipilimumab, requiring high-dose oral corticosteroids have also been reported[53]. The sequential administration of nivolumab-associated VKH disease has been reported with a positive clinical outcome[22].

The above evidence suggested that ICI-associated ophthalmic toxicity may be a potential marker for tumor response. As a result, the administration of corticosteroids requires careful consideration, because of possible compromise of antitumor activities of ICIs. Of note, some patients can also achieve a significant reduction of tumor burden through the symptomatic treatment for ocular adverse effects[102].

POSSIBLE MANAGEMENT OF OPHTHALMIC EVENTS AND FUTURE DIRECTIONS

Effective communication with a multidisciplinary team and primary care provider is essential for the prompt recognition and management of ICI-related ophthalmic events. In the era of anticancer immunotherapies, first, it is of great importance...
ICI-associated ophthalmic adverse events

for clinicians to distinguish ICI-related events from potential autoimmune-associated causes and common toxic adverse events. Second, it is vital that ophthalmologists do not mistake uveitis-like manifestations as purely inflammatory. The eye is an immune-privileged organ; even in the setting of an otherwise complete systemic response to therapy, it may be vulnerable to metastases. Two published case reports described cutaneous melanoma metastatic to the vitreous cavity and retina in patients treated with ICIs. These studies elucidated how such manifestations can be confused with inflammatory uveitis but require different management and may have an important impact on prognosis. Third, in the context of a diagnostic dilemma, eliciting a history of systemic irAEs and understanding ophthalmic irAEs that are rarely isolated are critical.

In general, most ophthalmic toxicities can initially be managed by periocular, topical, or systemic corticosteroids. In practice, when the ocular inflammation is mild or only covers the anterior segment, ICI discontinuation might not be required. Of course, the evaluation for the cessation or discontinuation of treatment will vary on a case-by-case basis depending on the severity and availability of ophthalmologic treatment. In severe or steroid-refractory cases, in which the symptoms are debilitating, it is necessary for ophthalmologists to consult with oncologists in determining the benefits and risk of cessation or continuation of ICIs. Immunotherapy discontinuation resulting in the spontaneous resolution of symptoms has rarely been reported. Steroids are required for most patients to alleviate the duration and intensity of symptoms. Alternative immunomodulatory therapies, such as intravenous immunoglobulin or plasma exchange, may offer additional benefits for patients with severe ophthalmologic events.

It is controversial whether ICIs should be re-introduced after recovery from ophthalmic toxicity. Although ophthalmic dysfunction can be significantly improved by corticosteroid therapy, an anti-PD1 agent re-challenge might induce symptom recurrence and even aggravate immune-related toxicities. In particular, the re-challenge of ICIs after a grade 3 toxicity requires extreme precaution. These recommendations may include some specific genres, such as uveitis, episcleritis, and blepharitis, but do not address other possible ocular presentations. It is important to be aware of the recurrence of adverse events after the re-introduction of ICIs. The management of the recurrence of ophthalmic toxicity is also challenging. As a result, the collaboration of clinical oncologists and ophthalmologists should give careful consideration to patients according to their presentations, outcomes, and alternative cancer therapy options to weigh the pros and cons of reintroducing immunotherapy.

CONCLUSION

ICIs, either alone or in combination with other therapies, can lead to ophthalmic adverse reactions, such as dry eyes, uveitis, ocular myasthenia gravis, uveal effusion, retinal detachment, conjunctivitis, ocular myositis, vasculitis, keratitis, episcleritis, and a wide spectrum of neuro-ophtalmic toxicities. Of all ICI-related ophthalmic events, dry eyes and uveitis are the most common ophthalmic adverse reactions. Although the incidence of ophthalmic toxicities induced by ICIs remains relatively low, oncologists and ophthalmologists must be vigilant for these adverse reactions because permanent damage and blindness can result from neglect. The time to onset and clinical presentations of ophthalmic irAEs are variable. They can occur at any time during treatment, including after the cessation of ICIs with nonspecific symptoms ranging from blurred vision, painless opthalmoplegia, diplopia, eyelid swelling, eye redness, floaters, exophthalmos, vision loss to shaped scotoma, headaches, and auditory changes. The assessment of ophthalmic evaluation in combination with autoimmune serologies, OCT, CSF, fundus examination, slit-lamp examination, fluorescein angiography, MRI, and biopsy, if necessary, contribute to the diagnosis of ICI-related ophthalmic adverse reactions. Among these diagnostic methods, ophthalmic evaluation is easily performed and has widespread availability. Before the initiation of ICIs, a comprehensive assessment of ophthalmic risk factors and a detailed ophthalmic history should be obtained, particularly for patients with autoimmune disease or pre-existing ophthalmic disease and in the context of ICIs combined with other regimens. For patients with confirmed ophthalmic events, most ophthalmic toxicities can initially be managed by periocular, topical or systemic corticosteroids. In severe or steroid-refractory cases, alternative immunomodulatory therapies, such as intravenous immunoglobulin or plasma exchange, might offer additional benefits. Ophthalmologists need to discuss with oncologists to determine the benefits and risks of discontinuing ICIs. Of note, ICI-associated ophthalmic events may be a potential positive marker for tumor response. In addition, ophthalmic function re-assessments and frequent monitoring are necessary. To better understand these events and provide effective therapy strategies, larger studies are needed.

ACKNOWLEDGEMENTS

Conflicts of Interest: Zhou YW, None; Xu Q, None; Wang Y, None; Xia RL, None; Liu JY, None; Ma XL, None.

REFERENCES

1. FDA approval summary: pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy. Oncologist 2017;22(7):873-878.


ICI-associated ophthalmic adverse events


Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab. *JAMA Ophthalmol 2016;134(10):1455-1457.*


ICI-associated ophthalmic adverse events


